Rejoinder: Understanding uncertainties in a change versus change study. by Fitz-Simon, Nicola et al.
Kennedy, SM; O’Driscoll, L; Purcell, R; Fitz-Simon, N; McDermott,
EW; Hill, AD; O’Higgins, NJ; Parkinson, M; Linehan, R; Clynes, M
(2003) Prognostic importance of survivin in breast cancer. British
journal of cancer, 88 (7). pp. 1077-83. ISSN 0007-0920
Downloaded from: http://researchonline.lshtm.ac.uk/1391/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Prognostic importance of survivin in breast cancer
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Survivin is a member of the inhibitor of apoptosis (IAP) family, and is also involved in the regulation of cell division. Survivin is widely
expressed in foetal tissues and in human cancers, but generally not in normal adult tissue. This study examined the expression of
surviving protein in a series of 293 cases of invasive primary breast carcinoma. Survivin immunoreactivity was assessed using two
different polyclonal antibodies, and evaluated semiquantitatively according to the percentage of cells demonstrating distinct nuclear
and/or diffuse cytoplasmic staining. Overall, 60% of tumours were positive for survivin: 31% demonstrated nuclear staining only, 13%
cytoplasmic only, and 16% of tumour cells demonstrated both nuclear and cytoplasmic staining. Statistical analysis revealed that
survivin expression was independent of patient’s age, tumour size, histological grade, nodal status, and oestrogen receptor status. In
multivariate analysis, nuclear survivin expression was a significant independent prognostic indicator of favourable outcome both in
relapse-free and overall survival (Po0.001 and P¼ 0.01, respectively). In conclusion, our results show that survivin is frequently
overexpressed in primary breast cancer. Nuclear expression is most common and is an independent prognostic indicator of good
prognosis.
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Apoptosis is the process whereby senescent or damaged cells are
eliminated. It is a multistep cascade regulated by proteins that
promote or counteract cell death. It is believed to be an important
mechanism by which therapeutic chemotherapy and radiation
therapy kill cancer cells. Aberrant inhibition of apoptosis interferes
with normal cell regulation and promotes tumour development
(for review, see Reed, 2001).
Survivin regulates cell division and inhibits apoptosis (Ambro-
sini et al, 1998). It is a member of the inhibitor of apoptosis (IAP)
family, which have been shown to inhibit activated caspases, the
cell death proteases either by acting directly (LaCasse et al, 1998;
Deveraux and Reed, 1999; Shin et al, 2001) or indirectly (O’Connor
et al, 2000; Reed, 2001).
Survivin mRNA was found to be diffusely expressed during
foetal development, but unusually, among the IAP family, it was
generally not found in normal adult tissues. In the majority of
cancers studied to date, survivin is associated with poor prognosis.
Survivin is overexpressed in most human cancers including
bladder (Swana et al, 1999), blood (Adida et al, 2000a, b),
colon (Kawasaki et al, 1998; Sarela et al, 2000), liver (Ito et al,
2000), brain (Nakagawara, 1998; Islam et al, 2000a), lung (Monzo
et al, 1999), pancreas (Satoh et al, 2001), prostate (Xing et al,
2001), and kidney (Takamizawa et al, 2001). Although most
immunohistochemical studies show survivin predominantly lo-
cated in the cytoplasm, in some tumours survivin may have a
mainly nuclear cellular location by immunohistochemistry (Ito
et al, 2000; Okada et al, 2001), and its expression in the nucleus
may be associated with a more favourable outcome (Okada et al,
2001).
Clinicopathological investigations on the role of survivin in
breast cancer focusing on its importance as a prognostic factor
have been limited. In this study, we investigated the prevalence
and cellular localisation of survivin in a consecutive retrospective
series of 293 primary breast cancers.
MATERIALS AND METHODS
Patient selection
The study material was derived from 293 consecutive cases of
primary breast cancer, on which clinical follow-up and pathologic
material, including snap-frozen tissue, were available for analysis
from the 1993–1997 files of St Vincent’s University Hospital
Pathology Department, Dublin, Ireland. The patients involved
underwent potentially curative resection at the hospital. A number
of clinical and pathologic parameters were abstracted from
patients’ charts including details on age, postoperative treatment
and follow– up, tumour stage, and hormonal analysis. Pathologic
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material was examined on each case by SK. Tumours were typed as
described by Page and Anderson (1987) and graded as described
by Elston and Ellis (1991). Staging was performed according to the
TNM system of the UICC (Sobin, 1997).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were immuno-
stained for survivin. Sections 4 mm thick were dewaxed in
xylene, rehydrated in alcohol, and blocked for endogenous
activity (3% H2O2 and normal rabbit serum). Antigen retrieval
was carried out by pressure cooking in citrate buffer, pH 6.0. The
sections were then incubated overnight at 41C with polyclonal
antibody AB469 (Novus Biologicals, Littleton, CO, USA) at
dilution of 1 : 400 for all cases. Eight tumours were also
investigated using the polyclonal antibody Surv 11A (Alpha
Diagnostics, San Antonio, Texas, USA) at a dilution of 1 : 25 in
order to check that the staining pattern was the same using a
different antibody. Sections were washed in PBS pH 7.4 to remove
unbound antisera. Bound antibody was detected using ABC
detection kit (Vector Laboratories, Burlingame, CA, USA) with
DAB as a chromogen. Slides were then lightly counterstained with
Crazzi’s haematoxylin.
Immunohistochemistry was also performed on 11 tumours snap
frozen at 601C. Sections 5 mm thick were cut and air-dried for 2 h,
fixed in acetone for 10 min, transferred to PBS, pH 7.4, and blocked
with normal serum. Following optimisation of the antibody for
frozen tissue, the sections were incubated with 1 : 150 dilution of
primary antibody (Novus Biologicals) overnight at 41C. Human
melanoma sections were used as positive controls and included in
each batch of 20 slides. An additional positive control used was a
breast carcinoma shown to contain survivin mRNA by RT–PCR
analysis. As a negative control, duplicate sections were stained
without exposure to primary antibodies.
Evaluation of immunohistochemistry results
Survivin immunoreactivity was evaluated semiquantitatively ac-
cording to the percentage of cells demonstrating distinct nuclear
and/or diffuse cytoplasmic immunohistochemical reaction. Nucle-
ar and cytoplasmic tumour cell immunoreactivities were separately
assessed in at least five high-power fields at  40 magnification
and assigned an arbitrary score as follows 0o5%; 1¼ 5– 20%;
2¼ 21–50%; 3¼ 51– 75%; 4476%. A cutoff value of 420% was
established as a positive result. Invasive tumours with a score of 0
or 1 were considered negative. The results were separately analysed
and statistically analysed. Two observers (SK, RP) separately
scored the cases and agreed upon any discrepancies at a double-
headed microscope.
Statistical analysis
Descriptive statistics were used to summarise patient character-
istics and statistical analysis of the results was performed
using Pearson’s w2 test to demonstrate the relation between
immunohistochemical and histopathologic findings. Kaplan–
Meier survival curves were established and subsequently checked
by log-rank, Breslow and Tarone-ware tests (P-values represent
log-rank, unless otherwise indicated) to assess the prognostic
significance of survivin expression in tumour cells. A value of
Po0.05 was considered statistically significant. Multivariate
analysis was performed with Cox regression model to assess
additional prognostic values of the different variables. Statistical
analyses were performed using Stata software (http://www.stata.
com/).
RESULTS
Patient characteristics
The patients were aged between 31 and 90 years at the time of
diagnosis (mean¼ 57.7 years). Ninety-two women were less than
50 years and 201 women were over 50 years at diagnosis. The size
of the tumours varied between 0.6 and 9 cm (mean¼ 2.67 cm).
Fifty-one tumours were T1 (o2 cm) in maximal dimension; 223
tumours were T2 (2–5 cm) and 19 tumours were T3 (45 cm). Two
hundered and forty-two tumours were invasive ductal carcinoma,
NOS; 39 were invasive lobular; and 12 were tumours of special type
(two tubular and 10 mucinous).
Twenty-four tumours were grade 1, 130 were grade 2, and 139
were grade 3. One hundred and ninety-four tumours were
oestrogen receptor positive and 87 were oestrogen receptor
negative (Oestrogen receptor status was determined by enzyme
immuno-assay (EIA). A positive result was defined as more than
200 fmol(g protein(1).). Oestrogen receptor status was not avail-
able for 12 patients. One hundred and thirty tumours had no
axillary metastases and 163 tumours had metastasised to axillary
lymph nodes.
One hundred and sixty-four women were treated with post-
operative tamoxifen, 111 did not receive tamoxifen. One hundred
and forty-six patients were treated with adjuvant systemic
chemotherapy (CMF +/ adriamycin). One hundred and thirty-
two patients did not receive chemotherapy. Details regarding
tamoxifen and systemic chemotherapy were not available for 18
and 15 patients, respectively. Maximal follow-up was 3471 days
with a mean follow-up of 1997 days (66.5 months). Six women
were lost to follow-up less than 1 year postsurgery. One hundred
and twenty-five patients had documented systemic metastases, 95
of whom died of disease and six patients had local recurrence. The
details are summarised in Table 1.
Immunohistochemical analysis
Specific staining for survivin was observed in tumour cells in
176 (60%) tumours. One hundred and seventeen tumours (40%)
did not express survivin above the cutoff value of 20%. The
breakdown of the distribution of survivin in tumours was as
follows: 38.7% score 1; 26.3% score 2; 25% score 3; and 10%
score 4.
We found that of the specimens that were survivin positive, 139
of 176 expressed survivin in the nuclear region of the tumour cell.
Figure 1A illustrates a typical example. In 91 specimens, the
reactivity was confined to the nucleus, and in 48 it was present in
both nucleus and cytoplasm as seen in Figure 1B. In 37
positive cases, survivin was expressed only in the cytoplasm.
Nuclear and cytoplasmic expression was occasionally seen in
ductal carcinoma in situ. There was focal, weak expression in some
normal ducts and lobules in cases where tumour cells showed
strong immunoreactivity. Stromal cells did not express survivin,
but peritumoral lymphocytes did react with survivin antibody in
some cases.
The immunohistochemical study of 11 frozen sections of cases
revealed unequivocal positivity in 10 cases. Seven cases had
immunoreactivity of tumour cells in the nucleus alone. In three
cases, there was nuclear and cytoplasmic positivity in tumour cells.
In each case, the pattern correlated with that of the corresponding
formalin-fixed, paraffin-embedded tissue.
Eight formalin-fixed paraffin-embedded tumour cases also were
examined with a second survivin antibody (Alpha Diagnostics). In
three cases, immunoreactivity was confined to the nucleus; in three
cases, it was confined to the cytoplasm; and in two cases, there was
both cytoplasmic and nuclear immunoreactivity. These results
correlated with those of the Novus antibody in seven of the eight
cases.
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Statistical analysis
To evaluate the prognostic significance of survivin expression at
diagnosis, survivin expression was analysed in relation to relapse-
free survival (RFS) and Overall survival. In a Cox univariate
analysis for RFS in all patients, nuclear survivin o20% was
significantly associated with a shortened RFS. Similarly, grade, ER
status, nodal status, and size were significantly related to RFS in
univariate analysis. On the other hand, cytoplasmic survivin
expression, age at diagnosis, and treatment (adjuvant or hormonal
therapy) were not significantly related to RFS in univariate analysis
(Table 1). There was no significant association between nuclear
survivin expression levels and any other clinicopathologic feature
analysed (Table 2). There was no statistical significance when
looking at the effect of chemotherapy on survival between
survivin-negative and survivin-positive tumours.
In multivariate analysis, the most important prognostic factors
for disease-free survival were negative lymph node status
(Po0.001), size (P¼ 0.046), nuclear survivin expression (cutoff
point¼ 20% (Po0.001)), and oestrogen receptor status among
lymph node-positive patients (P¼ 0.042) (Table 3). The Kaplan–
Meier survival curves demonstrate the better prognosis of nuclear
survivin-positive tumours for disease-free (Figure 2A) and overall
survival (Figure 2B).
In terms of overall survival, the most important prognostic
factors were size (P¼ 0.016), grade (P¼ 0.012), nuclear survivin
expression (P¼ 0.010), and lymph node status (P¼ 0.044) (Table
4). The hazard ratios in the multivariate Cox models give the risk
of relapse/death adjusted for time and the other covariates, for
example, lymph node status. This analysis shows that patients
whose tumours have nuclear survivin in 420% of tumour cells
have approximately half (0.5663) the risk of death or relapse
compared to the women whose tumours have negative or below
cutoff level of nuclear survivin.
Nuclear survivin expression is an independent favourable
prognostic indicator for both disease-free and overall survival.
The effect of cytoplasmic positivity alone shows a similar trend,
but is less significant as numbers of positive cases are smaller. The
relative risk of death or systemic relapse in patients whose
tumours are survivin negative compared with those whose
tumours are survivin positive is 1.76.
DISCUSSION
The aim of our study was to investigate the expression of survivin
protein in invasive breast carcinoma by immunohistochemistry.
Survivin protein was detected in 60% of tumours. It was most
commonly located in the nucleus (139 of 176 positive cases), but
was seen in a minority (85 of 176 positive cases) of tumours in the
Table 1 Characteristics of 293 patients and univariate significance for
relapse-free survival of selected parameters
Characteristic Number of patients % P-valuea
Age (years)
p60 172 59 n.s.
460 121 41
Histological grade
I+II 154 53 o0.0001
III 139 47
Lymph node status
Node  130 44 0.0001
Node + 163 56
ER status
+(X10 fm mg1) 194 66 0.0001
(o10 fm mg1) 87 30
Unknown 12 4
Tumour sizeb (cm)
p2.8 146 50 0.002
42.8 147 50
Nuclear survivin (%)
420 139 47 0.0033
p20 154 53
Cytoplasmic survivin
Pos 85 29 n.s.
Neg 208 71
Adjuvant chemotherapy
Yes 146 50 n.s.
No 132 45
Unknown 15 5
Tamoxifen
Yes 164 56 n.s.
No 111 38
Unknown 18 6
aLog-rank test . b2.8 cm=median tumour size. n.s.=not significant .
Figure 1 Infiltrating tumour cells showing (A) distinct nuclear positivity
with polyclonal antibody to survivin ( 200 magnification) and (B) both
nuclear and cytoplasmic positivity with antisurvivin antibody ( 400
magnification).
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cytoplasm. In multivariate analysis, the presence of survivin
protein in invasive breast cancers is a strong independent
prognostic indicator of 5-year RFS and overall survival.
A lack of consensus exists regarding the importance of
intracellular location and prognostic significance of survivin
expression in common epithelial tumours. Survivin was originally
reported by Ambrosini et al (1997) to be present during foetal life
but undetectable in adult differentiated tissues (Ambrosini et al,
1997). It is also expressed at mRNA and protein level in a range of
common epithelial tumours including colon (Sarela et al, 2000),
pancreas (Satoh et al, 2001), prostate (Xing et al, 2001), and breast
(Tanaka et al, 2000). As a result of this widespread expression in
tumours, and generally low-level expression in normal tissue,
survivin was considered to be a potentially valuable new target for
apoptosis-based chemotherapy. Subsequent studies have shown
that survivin is expressed in the normal endometrium (Konno et al,
2000). It is expressed in the nucleus and cytoplasm of basal and
glandular cells, in a pattern correlating with proliferative and
secretory phase of the menstrual cycle. Survivin expression has
been found in normal colon as well as in hyperplastic polyps,
adenomatous polyps, and colonic adenocarcinoma (Gianani et al,
2001).
Our findings that survivin subcellular location may be
predominantly nuclear in breast carcinoma and that its presence
may be a favourable prognostic indicator are at variance with one
previous report of the significance of survivin protein expression
in invasive breast carcinoma. The study by Tanaka et al (2000)
used an antibody (mAb 8E2, provided by Dr DC Altieri, Yale
University, CT, USA) different from the one we used. There is a
suggestion that this antibody may detect cytoplasmic survivin only
(Fortugno et al, 2002). Their results show a trend towards
association between cytoplasmic survivin and a bad prognosis.
This was not statistically significant. They found that apoptotic
index (AI) is an independent prognostic indicator and they found
a significant correlation between AI and cytoplasmic survivin.
They inferred from this a relation between cytoplasmic survivin
and poor prognosis. It is also possible that other apoptotic factors
may have contributed to the decreased AI in the tumours that
relapsed. Our results show a statistically significant relation
between nuclear survivin expression and good prognosis.
Our study showed no correlation between survivin expression
and other clinicopathological prognostic features including
tumour size. Our study population only included 17% pT1
tumours, but there were 95 (35%) tumours p2 cm and a linear
relation exists between size increase and probability of relapse. In
our study, we found that there was strong evidence of a correlation
between high levels of nuclear survivin and increased survival time
to relapse or death.
Okada et al (2001) reported survivin expression in the nucleus
as well as in the cytoplasm in gastric cancer. Nuclear localisation
was associated with favourable prognosis in multivariate analysis.
Cytoplasmic survivin expression was associated with a poor
prognosis. In a study of hepatocellular carcinomas, survivin
expression was mainly in the nucleus with weak cytoplasmic
staining of tumour cells and no expression in normal tissues (Ito
et al, 2000). Also, survivin did not significantly correlate with the
AI as calculated by the TUNEL method in hepatocellular
carcinoma.
Survivin has been described both as a chromosomal passenger
protein in the nucleus and as a cytoplasmic microtubule-associated
protein. Survivin is normally expressed in the G2/M phase of the
cell cycle in a cell-cycle-regulated manner, and is associated with
microtubules of the mitotic spindle during mitosis (Li et al, 1998).
Disruption of survivin– microtubule interactions has been pro-
posed to result in loss of survivin’s antiapoptosis function and
increased caspase-3 activity during mitosis (Tamm et al, 1998; Li
et al, 1999).
Fortugno et al (2002), in a study using a novel panel of
monoclonal and polyclonal antibodies, have shown that there are
different subcellular pools of survivin. A nuclear pool that
segregates with nucleoplasmic proteins was identified. A separate
and predominant cytosolic pool associates with interphase
microtubules, centrosomes, spindle poles, and mitotic spindle
microtubules at metaphase and anaphase. The two survivins are
immunochemically distinct, independently modulated during cell
cycle progression and only cytosolic survivin associates with
p34cdc2. Phosphorylation of survivin by p34cdc2 – cyclin B has been
identified as a requisite for apoptosis inhibition (O’Connor et al,
2000). The postulated explanation for these findings was that
Table 2 Correlation between clinicopathologic factors and expression of
nuclear survivin in breast cancer
Nuclear survivin expression
Negativea
(n=154)
Positiveb
(n=139) P-value
Age (years)
p60 93 89 n.s.
460 61 50
Histological grade
I+II 75 79 n.s.
III 79 60
Lymph node status
Node  76 88 n.s.
Node + 78 51
ER status
+ (X10 fm mg1) 96 99 n.s.
 (o10 fm mg1) 51 35
Unknown 7 5
Tumour size (cm)
p2.8 77 71 n.s.
42.8 77 68
Adjuvant chemotherapy
Yes 76 70 n.s.
No 68 64
Unknown 10 5
Tamoxifen
Yes 91 73 n.s.
No 51 60
Unknown 12 6
ap20% nuclear survivin expression. b420% nuclear survivin expression. n.s.=not
significant .
Table 3 Multivariate analysis for disease-free survival
Variables
Hazard
ratio s.e. Coefficient P-value
Nodal status 3.295789 1.069509 3.68 o0.001
ERa 0.7868536 0.2716365 0.69 0.487
ER LN positiveb 0.4310035 0.1781777 2.04 0.042
Sizec 1.477919 0.289276 2.00 0.046
Graded 1.466601 0.2992795 1.88 0.061
Nuclear survivine 0.4846783 0.094241 3.72 o0.001
aEstrogen receptor positive vs negative. bEffect of ER status on survival where lymph
node metastases have occurred. cDichotomised size variable using the median
(2.8 cm) as the cutoff. dGrades I and II grouped together vs grade III. eDichotomised
nuclear survivin, cutoff=20%.
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separate post-translational modifications could differentially affect
epitope accessibility of nuclear vs cytosolic microtubule-bound
survivin in vivo. If nuclear survivin cannot associate with p34, an
essential step in apoptosis inhibition, it may actually induce
apoptosis. This may explain why different patterns of survivin
localisation are seen in different tumour types and may partly
explain the different prognostic implications of cytoplasmic and
nuclear survivin. Survivin may be only effective in blocking
apoptosis when located in the cytosol where caspases are
predominantly located. Nuclear survivin must be phosphorylated
for binding to processed caspase-9. A nonphosphorylatable alanine
(T34A) mutant of survivin has been described, which disrupts cell
division and induces apoptosis, probably by substrate competition
(O’Connor et al, 2000).
Recently, splice variants of survivin with different antiapoptotic
properties have been identified (Mahotka et al, 1999; Fogt et al,
2001; Krieg et al, 2002). One of these variants, survivin-2B, has
reduced antiapoptotic potential and may act as a naturally
occurring antagonist of survivin. In a study of gastric carcinomas,
all gastric carcinomas were found to express mRNA encoding the
splice variants survivin delta EX 3 and survivin-2B as well as
survivin. In that study, there was a decrease in survivin-2B mRNA
in higher stage disease. Polyclonal antibodies, such as the
antibodies used in the current study, will react with all survivin
variants except the delta EX 3 variant with the Alpha Diagnostics
antibody. Our results showed a good correlation between two
antibodies on a limited panel of formalin-fixed and fresh breast
cancer tissue.
Our data show that polyclonal antibodies to survivin detect
both cytoplasmic and nuclear forms of survivin in breast cancer.
The nuclear form is most common and is an independent
prognostic indicator of good outcome. This is surprising in view
of reports on other common epithelial tumour types showing that
survivin expression is associated with a worse outcome, but has
analogies with the other main apoptosis inhibitor bcl-2 whose
overexpression is associated with a better outcome in breast
cancer and a favourable response to therapy (Leek et al, 1994;
Duenas-Gonzalez et al, 1997). The reason for this apparent
contradiction lies in the interaction of bcl-2 with other family
members, for example, Bax. The ratio of Bcl-2 to Bax and the
ability of Bcl-2 to form homo- and heterodimers holds the key to
the regulation of the balance between cell survival and apoptosis.
We hypothesise that survivin is of a similar nature, that different
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Figure 2 Kaplan–Meier estimates for (A) disease-free survival and (B) overall survival, by nuclear survivino20 vsX20%, adjusted for cytoplasmic result,
oestrogen receptor status, lymph node status, grade, and size.
Table 4 Multivariate analysis for overall survival
Variables
Hazard
ratio s.e. Coefficient P-value
Nodal status 1.625208 0.3916559 2.02 0.044
Sizea 2.335183 0.8202764 2.41 0.016
Gradeb 1.790949 0.4176715 2.50 0.012
Nuclear survivinc 0.5663471 0.1249786 2.58 0.010
Model is stratified using quartiles of age.aDichotomised size variable using the median
(2.8 cm) as the cutoff. bGrades I and II grouped together vs grade III. cDichotomised
nuclear survivin, cutoff=20%.
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splice variants may interact, and subcellular location ratio of the
protein may contribute to a complex regulation of apoptosis.
This hypothesis is supported by the suggestion that survivin-2B
may impair or oppose the function of survivin, acting in a
dominant-negative manner (Islam et al, 2000b). Our results are in
agreement with the reported study of gastric carcinomas (Okada
et al, 2001), where nuclear staining is associated with favourable
prognosis.
Intracellular location of survivin may have an important
physiologic role in the cell cycle and have different prognostic
implications, as in the case of cyclin D2. Nuclear localisation of
cyclin D2 has been reported to have good prognostic import. It is
associated with well-differentiated tumours, lower depth of cancer
invasion, fewer lymph node metastases, and less vessel invasion. In
contrast, cytoplasmic location of cyclin D2 is associated with a
poor prognosis (Takano et al, 1999, 2000).
Absence of survivin in node-negative breast cancer patients may
herald a higher risk of relapse and a shorter survival. Further
studies on breast cancer, when selective antibodies become
available, may elucidate the role of survivin, including its location
and possibly antagonistic roles of splice variants in apoptosis
inhibition and cell cycle control in breast cancer.
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